New drug combo takes on tough liver cancer
NCT ID NCT06600321
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug called ALN-BCAT, given alone or with the immunotherapy Keytruda, in people with advanced or metastatic liver cancer that has a specific genetic mutation (WNT pathway). The trial aims to find safe doses and see if the drugs shrink tumors. About 158 participants will be enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ALN-BCAT (a drug given by IV) and pembrolizumab (Keytruda, an immunotherapy drug given by IV)
- What this could lead to
- If it works, this could point toward a new treatment option for advanced liver cancer that has not responded to other therapies.
- What could go wrong
- This is a very early (Phase 1) trial focused on safety and dosing, so it may not show strong anti-tumor effects. Side effects from the drugs are possible, and the combination may not work better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Clinical Trial Site
RECRUITINGPhoenix, Arizona, 85054, United States
-
Clinical Trial Site
RECRUITINGLa Jolla, California, 92037, United States
-
Clinical Trial Site
RECRUITINGLos Angeles, California, 90033, United States
-
Clinical Trial Site
RECRUITINGJacksonville, Florida, 32224, United States
-
Clinical Trial Site
RECRUITINGAtlanta, Georgia, 30322, United States
-
Clinical Trial Site
RECRUITINGChicago, Illinois, 60637, United States
-
Clinical Trial Site
RECRUITINGAnn Arbor, Michigan, 48109, United States
-
Clinical Trial Site
RECRUITINGRochester, Minnesota, 55905, United States
-
Clinical Trial Site
RECRUITINGNew York, New York, 10029, United States
-
Clinical Trial Site
COMPLETEDNew York, New York, 10032, United States
-
Clinical Trial Site
RECRUITINGCleveland, Ohio, 44106, United States
-
Clinical Trial Site
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
-
Clinical Trial Site
RECRUITINGDallas, Texas, 75390, United States
-
Clinical Trial Site
RECRUITINGHouston, Texas, 77030, United States
-
Clinical Trial Site
RECRUITINGSan Antonio, Texas, 78229, United States
-
Clinical Trial Site
RECRUITINGRichmond, Virginia, 23298, United States
-
Clinical Trial Site
RECRUITINGMilan, 20132, Italy
-
Clinical Trial Site
RECRUITINGRozzano, 20089, Italy
-
Clinical Trial Site
RECRUITINGVerona, 37134, Italy
-
Clinical Trial Site
RECRUITINGBusan, 49241, South Korea
-
Clinical Trial Site
RECRUITINGSeongnam, 13496, South Korea
-
Clinical Trial Site
RECRUITINGSeongnam, 13620, South Korea
-
Clinical Trial Site
RECRUITINGSeoul, 03722, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an IDO1 inhibitor boost immunotherapy against liver cancer?
- 3D MRI scan may predict liver cancer treatment success
- New scan could spot hidden cancer left behind after liver surgery
- 3D liver stiffness scan could predict surgery risks
- Immunotherapy drug durvalumab may be safe for liver cancer patients with active hepatitis b
- Immunotherapy-Targeted therapy combo shows promise for advanced liver cancer